UNLABELLED: The inherent sequence diversity of the hepatitis C virus (HCV) with the existence of multiple genotypes that differ up to 20% at the amino acid level represents one of the major obstacles for immune control. Accordingly, immune control of a heterologous virus challenge, particularly across genotypes, is difficult to achieve; however, the overall role of genotype-specific sequence differences has not yet been defined at the epitope level. The aim of this study was to determine the role of genotype-specific sequence differences for the CD8+ T cell response against HCV. We analyzed a cohort of anti-HCV-positive injection drug users infected with HCV genotype 1 (n = 17) or genotype 3 (n = 22) or undetectable HCV-RNA (n = 14) with overlapping peptides covering consensus sequences of NS3 from both genotypes. Importantly, the majority of HCV-specific CD8 T cells were specific for one genotype only indicating that sequence differences between genotypes are relevant at the epitope level. Interestingly, T cells active against both genotypes were significantly more frequent in HCV-RNA-negative subjects. Of note, we identified five subjects with undetectable viremia and coexistence of two T cell populations-one for each genotype-suggesting immune control of two different genotypes. CONCLUSION: We systematically analyzed the degree of cross-genotype reactivity of HCV-specific T cells and have shown that CD8 responses targeting different HCV genotypes can be primed in the same individual and that such responses potentially characterize a subgroup among injection drug users being protected from chronic HCV infection.
UNLABELLED: The inherent sequence diversity of the hepatitis C virus (HCV) with the existence of multiple genotypes that differ up to 20% at the amino acid level represents one of the major obstacles for immune control. Accordingly, immune control of a heterologous virus challenge, particularly across genotypes, is difficult to achieve; however, the overall role of genotype-specific sequence differences has not yet been defined at the epitope level. The aim of this study was to determine the role of genotype-specific sequence differences for the CD8+ T cell response against HCV. We analyzed a cohort of anti-HCV-positive injection drug users infected with HCV genotype 1 (n = 17) or genotype 3 (n = 22) or undetectable HCV-RNA (n = 14) with overlapping peptides covering consensus sequences of NS3 from both genotypes. Importantly, the majority of HCV-specific CD8 T cells were specific for one genotype only indicating that sequence differences between genotypes are relevant at the epitope level. Interestingly, T cells active against both genotypes were significantly more frequent in HCV-RNA-negative subjects. Of note, we identified five subjects with undetectable viremia and coexistence of two T cell populations-one for each genotype-suggesting immune control of two different genotypes. CONCLUSION: We systematically analyzed the degree of cross-genotype reactivity of HCV-specific T cells and have shown that CD8 responses targeting different HCV genotypes can be primed in the same individual and that such responses potentially characterize a subgroup among injection drug users being protected from chronic HCV infection.
Authors: Andreas Walker; Kathrin Skibbe; Eike Steinmann; Stephanie Pfaender; Thomas Kuntzen; Dominik A Megger; Svenja Groten; Barbara Sitek; Georg M Lauer; Arthur Y Kim; Thomas Pietschmann; Todd M Allen; Joerg Timm Journal: J Virol Date: 2015-10-07 Impact factor: 5.103
Authors: Victor Max Corman; Adam Grundhoff; Christine Baechlein; Nicole Fischer; Anatoly Gmyl; Robert Wollny; Dickson Dei; Daniel Ritz; Tabea Binger; Ernest Adankwah; Kwadwo Sarfo Marfo; Lawrence Annison; Augustina Annan; Yaw Adu-Sarkodie; Samuel Oppong; Paul Becher; Christian Drosten; Jan Felix Drexler Journal: J Virol Date: 2015-03-18 Impact factor: 5.103
Authors: Christoph Neumann-Haefelin; Jörg Timm; Julia Schmidt; Nadine Kersting; Karen Fitzmaurice; Cesar Oniangue-Ndza; Michael N Kemper; Isla Humphreys; Susan McKiernan; Dermot Kelleher; Volker Lohmann; Paul Bowness; Daniela Huzly; Hugo R Rosen; Arthur Y Kim; Georg M Lauer; Todd M Allen; Eleanor Barnes; Michael Roggendorf; Hubert E Blum; Robert Thimme Journal: Hepatology Date: 2010-01 Impact factor: 17.425
Authors: Marianne Ruhl; Patrick Chhatwal; Heiko Strathmann; Thomas Kuntzen; Dorothea Bankwitz; Kathrin Skibbe; Andreas Walker; Falko M Heinemann; Peter A Horn; Todd M Allen; Daniel Hoffmann; Thomas Pietschmann; Jörg Timm Journal: J Virol Date: 2011-11-09 Impact factor: 5.103
Authors: Isla S Humphreys; Annette von Delft; Anthony Brown; Linda Hibbert; Jane D Collier; Graham R Foster; Monira Rahman; Annabel Christian; Paul Klenerman; Eleanor Barnes Journal: Gut Date: 2012-02-15 Impact factor: 23.059